We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Novel Saliva-Based PCR Assay Detects HIV Antibodies Earlier

By LabMedica International staff writers
Posted on 28 Feb 2018
An oral fluid-based test for human immunodeficiency virus (HIV) shows promise as a population-based screening tool. More...
According to its developers, the test is easier to collect than blood but yields results that are just as reliable.

In comparison to blood, which poses an infection risk to healthcare workers, oral fluid is not infectious. However, the problem with human saliva is it contains very few anti-HIV antibodies, the markers of HIV infection, and current oral fluid assays do not detect HIV as quickly or efficiently as blood tests.

Scientists at Stanford University (Stanford, CA, USA) have demonstrated how a new oral fluid test, the Antibody Detection by Agglutination– PCR (ADAP) technology, was able to successfully detect HIV at the early stages. The developers of ADAP analyzed how antibodies latch on to the HIV virus to create a more sensitive oral fluid test that was 1,000 to 10,000 times more sensitive than clinical enzyme-linked immunoassays in finding HIV antibodies. ADAP uses polymerase chain reaction (PCR), a technique often used to detect DNA, to find HIV antibodies.

The team used ADAP technology to accurately diagnose 22 individuals who participated in Alameda County Public Health Laboratory’s HIV screening program and had been diagnosed with HIV through other methods. Overall, it yielded 100% clinical sensitivity and 100% specificity for detecting these antibodies from oral fluids. The test also did not produce any false positive results in 22 additional individuals who were HIV negative. The enhanced analytical sensitivity enables this assay to correctly identify HIV-infected individuals otherwise missed by current oral fluid (OF) assays.

Carolyn R. Bertozzi, PhD, a professor of chemistry and the lead investigator of the study, said, “PCR is very sensitive, it can detect very low amounts of the target DNA, whereas techniques people use to detect proteins are far less sensitive. Our test brings the sensitivity of PCR to the testing of proteins, the HIV antibodies in oral fluid, more specifically. We can reset the standards for oral fluid diagnostic sensitivity, bringing it closer to that of blood tests but with convenience of oral fluid. ” The study was published on February 6, 2018, in the journal Proceedings of the National Academy of Sciences.

Related Links:
Stanford University


Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Portable Electronic Pipette
Mini 96
New
Gold Member
Collection and Transport System
PurSafe Plus®
New
Alcohol Testing Device
Dräger Alcotest 7000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: New research points to protecting blood during radiation therapy (Photo courtesy of 123RF)

Pioneering Model Measures Radiation Exposure in Blood for Precise Cancer Treatments

Scientists have long focused on protecting organs near tumors during radiotherapy, but blood — a vital, circulating tissue — has largely been excluded from dose calculations. Each blood cell passing through... Read more

Immunology

view channel
Image: The VENTANA HER2 (4B5) test is now CE-IVDR approved (Photo courtesy of Roche)

Companion Diagnostic Test Identifies HER2-Ultralow Breast Cancer and Biliary Tract Cancer Patients

Breast cancer is the most common cancer in Europe, with more than 564,000 new cases and 145,000 deaths annually. Metastatic breast cancer is rising in younger populations and remains the leading cause... Read more

Technology

view channel
Image: Conceptual design of the CORAL capsule for microbial sampling in the small intestine (H. Mohammed et al., Device (2025). DOI: 10.1016/j.device.2025.100904)

Coral-Inspired Capsule Samples Hidden Bacteria from Small Intestine

The gut microbiome has been linked to conditions ranging from immune disorders to mental health, yet conventional stool tests often fail to capture bacterial populations in the small intestine.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.